Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

• Paul B Chapman, A. H. W. Hauschild, +25 authors Grant Mcarthur
• The New England journal of medicine
• 2011

BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E… (More)

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

• Ramin Nazarian, Hubing Shi, +13 authors Roger S. Lo
• Nature
• 2010

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor,… (More)

Inhibition of mutated, activated BRAF in metastatic melanoma.

• Keith T. Flaherty, Igor J. Puzanov, +8 authors Paul B Chapman
• The New England journal of medicine
• 2010

BACKGROUND The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted… (More)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

• James Larkin, Vanna Chiarion-Sileni, +28 authors Jedd D Wolchok
• The New England journal of medicine
• 2015

BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have… (More)

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

• Jessie Villanueva, A Vultur, +18 authors Meenhard Herlyn
• Cancer cell
• 2010

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF inhibitors developed… (More)

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

• Jeffrey A. Sosman, Kevin B Kim, +22 authors Antoni Ribas
• The New England journal of medicine
• 2012

BACKGROUND Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced… (More)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

• Gideon E. Bollag, Peter Hirth, +37 authors Keith B. Nolop
• Nature
• 2010

B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are… (More)

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

• James M. G. Larkin, Paolo Antonio Ascierto, +16 authors Antoni Ribas
• The New England journal of medicine
• 2014

BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF… (More)

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

• Fei Su, Amaya Virós, +50 authors Richard Marais
• The New England journal of medicine
• 2012

BACKGROUND Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors. METHODS We performed a molecular analysis to identify oncogenic… (More)

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

• Antoni Ribas, Richard Kefford, +21 authors A. H. W. Hauschild
• Journal of clinical oncology : official journal…
• 2013

PURPOSE In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of patients with advanced melanoma. This… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›